Tumour-infiltrating lymphocytes - Revision history

Michael: /* Tumours with abundant lymphocytes as a component */

2021-06-25T16:05:26Z

Tumours with abundant lymphocytes as a component

← Older revision		Revision as of 16:05, 25 June 2021
Line 29:		Line 29:
	*[[Thymoma]].		*[[Thymoma]].
	*[[Follicular dendritic cell sarcoma]].		*[[Follicular dendritic cell sarcoma]].
			*[[Seminoma]].
	*Others.		*Others.

Michael: /* General */ tweak

2018-11-29T14:29:40Z

General: tweak

← Older revision		Revision as of 14:29, 29 November 2018
Line 11:		Line 11:
	\|-		\|-
	\| [[Colorectal carcinoma]]		\| [[Colorectal carcinoma]]
	\| TILs associated with [[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>		\| [[Intratumoural lymphocytic response in colorectal carcinoma\|TILs in CRC]] are associated with [[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>
	\|-		\|-
	\| [[Malignant melanoma]]		\| [[Malignant melanoma]]

Michael: /* Tumours with abundant lymphocytes as a component */

2016-05-25T14:40:25Z

Tumours with abundant lymphocytes as a component

← Older revision		Revision as of 14:40, 25 May 2016
Line 29:		Line 29:
	*[[Thymoma]].		*[[Thymoma]].
	*[[Follicular dendritic cell sarcoma]].		*[[Follicular dendritic cell sarcoma]].
			*Others.

	==See also==		==See also==

Michael at 14:40, 25 May 2016

2016-05-25T14:40:17Z

← Older revision		Revision as of 14:40, 25 May 2016
Line 23:		Line 23:
	\|-		\|-
	\|}		\|}

			==Tumours with abundant lymphocytes as a component==
			*[[Nasopharyngeal carcinoma]].
			*[[Lymphoepithelioma-like carcinoma]].
			*[[Thymoma]].
			*[[Follicular dendritic cell sarcoma]].

	==See also==		==See also==

Michael: /* See also */

2016-05-25T14:34:24Z

Michael: /* General */

2016-05-04T04:28:16Z

General

← Older revision		Revision as of 04:28, 4 May 2016
Line 14:		Line 14:
	\|-		\|-
	\| [[Malignant melanoma]]		\| [[Malignant melanoma]]
	\| TILs better ~~survivall~~<ref>{{Cite journal \| last1 = Lee \| first1 = N. \| last2 = Zakka \| first2 = LR. \| last3 = Mihm \| first3 = MC. \| last4 = Schatton \| first4 = T. \| title = Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. \| journal = Pathology \| volume = 48 \| issue = 2 \| pages = 177-87 \| month = Feb \| year = 2016 \| doi = 10.1016/j.pathol.2015.12.006 \| PMID = 27020390 }}</ref>		\| TILs better survival<ref>{{Cite journal \| last1 = Lee \| first1 = N. \| last2 = Zakka \| first2 = LR. \| last3 = Mihm \| first3 = MC. \| last4 = Schatton \| first4 = T. \| title = Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. \| journal = Pathology \| volume = 48 \| issue = 2 \| pages = 177-87 \| month = Feb \| year = 2016 \| doi = 10.1016/j.pathol.2015.12.006 \| PMID = 27020390 }}</ref>
	\|-		\|-
	\|[[Non-small cell lung cancer]]		\|[[Non-small cell lung cancer]]

Michael: /* General */

2016-05-04T04:28:05Z

General

← Older revision		Revision as of 04:28, 4 May 2016
Line 11:		Line 11:
	\|-		\|-
	\| [[Colorectal carcinoma]]		\| [[Colorectal carcinoma]]
	\| [[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>		\| TILs associated with [[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>
	\|-		\|-
	\| [[Malignant melanoma]]		\| [[Malignant melanoma]]
	\|		\| TILs better survivall<ref>{{Cite journal \| last1 = Lee \| first1 = N. \| last2 = Zakka \| first2 = LR. \| last3 = Mihm \| first3 = MC. \| last4 = Schatton \| first4 = T. \| title = Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. \| journal = Pathology \| volume = 48 \| issue = 2 \| pages = 177-87 \| month = Feb \| year = 2016 \| doi = 10.1016/j.pathol.2015.12.006 \| PMID = 27020390 }}</ref>
	\|-		\|-
	\|[[Non-small cell lung cancer]]		\|[[Non-small cell lung cancer]]
	\| associated with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = \| issue = \| pages = \| month = Mar \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>		\| TILs associated with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = \| issue = \| pages = \| month = Mar \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>
	\|-		\|-
	\| [[Ovarian serous carcinoma]]		\| [[Ovarian serous carcinoma]]
	\| good prognosis<ref name=pmid26972336>{{Cite journal \| last1 = Webb \| first1 = JR. \| last2 = Milne \| first2 = K. \| last3 = Kroeger \| first3 = DR. \| last4 = Nelson \| first4 = BH. \| title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. \| journal = Gynecol Oncol \| volume = 141 \| issue = 2 \| pages = 293-302 \| month = May \| year = 2016 \| doi = 10.1016/j.ygyno.2016.03.008 \| PMID = 26972336 }}</ref>		\| TILs associated with good prognosis<ref name=pmid26972336>{{Cite journal \| last1 = Webb \| first1 = JR. \| last2 = Milne \| first2 = K. \| last3 = Kroeger \| first3 = DR. \| last4 = Nelson \| first4 = BH. \| title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. \| journal = Gynecol Oncol \| volume = 141 \| issue = 2 \| pages = 293-302 \| month = May \| year = 2016 \| doi = 10.1016/j.ygyno.2016.03.008 \| PMID = 26972336 }}</ref>
	\|-		\|-
	\|}		\|}

Michael: /* See also */

2016-05-04T04:12:04Z

Michael: /* See also */

2016-05-04T04:11:26Z

Michael: /* General */

2016-05-04T04:05:05Z

General

← Older revision		Revision as of 04:05, 4 May 2016
Line 10:		Line 10:
	!Association		!Association
	\|-		\|-
	\|Colorectal carcinoma		\| [[Colorectal carcinoma]]
	\|[[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>		\| [[Microsatellite instability in colorectal cancer\|microsatellite instability]]<ref name=pmid21114775>{{Cite journal \| last1 = Iacopetta \| first1 = B. \| last2 = Grieu \| first2 = F. \| last3 = Amanuel \| first3 = B. \| title = Microsatellite instability in colorectal cancer. \| journal = Asia Pac J Clin Oncol \| volume = 6 \| issue = 4 \| pages = 260-9 \| month = Dec \| year = 2010 \| doi = 10.1111/j.1743-7563.2010.01335.x \| PMID = 21114775 }}</ref>
	\|-		\|-
	\|[[Malignant melanoma]]		\| [[Malignant melanoma]]
	\|		\|
	\|-		\|-
	\|[[Non-small cell lung cancer]]		\|[[Non-small cell lung cancer]]
	\|~~assoc.~~ with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = \| issue = \| pages = \| month = Mar \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>		\| associated with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = \| issue = \| pages = \| month = Mar \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>
	\|-		\|-
	\| [[Ovarian serous carcinoma]]		\| [[Ovarian serous carcinoma]]

← Older revision		Revision as of 14:34, 25 May 2016
Line 28:		Line 28:
	*[[Intratumoural lymphocytic response in colorectal carcinoma]].		*[[Intratumoural lymphocytic response in colorectal carcinoma]].
	*[[Peritumoural lymphocytic response]] (Crohn's like reaction).		*[[Peritumoural lymphocytic response]] (Crohn's like reaction).
			*[[Intraepithelial lymphocytes]].

	==References==		==References==

← Older revision		Revision as of 04:12, 4 May 2016
Line 27:		Line 27:
	*[[PD-L1]].		*[[PD-L1]].
	*[[Intratumoural lymphocytic response in colorectal carcinoma]].		*[[Intratumoural lymphocytic response in colorectal carcinoma]].
	*[[Crohn's-like reaction]].		*[[Peritumoural lymphocytic response]] (Crohn's like reaction).

	==References==		==References==

← Older revision		Revision as of 04:11, 4 May 2016
Line 26:		Line 26:
	==See also==		==See also==
	*[[PD-L1]].		*[[PD-L1]].
			*[[Intratumoural lymphocytic response in colorectal carcinoma]].
			*[[Crohn's-like reaction]].

	==References==		==References==